Increased interleukin-10 serum levels in patients with solid tumours

doi:10.1016/0304-3835(96)04213-9

Cancer Letters

Volume 104, Issue 1, 24 June 1996, Pages 1-5

https://doi.org/10.1016/0304-3835(96)04213-9 Get rights and content

Abstract

In 40 out of 99 patients (40.4%) with solid tumours of different tissue, but the same stage (IV), elevated serum levels of interleukin-10 were observed. The mean levels of the cytokine in patients with malignant melanoma (24.3 ng/ml), pancreatic (6.8 ng/ml) or gastric (6.3 ng/ml) adenocarcinoma were significantly higher than in healthy subjects (3.4 ng/ml) or in patients with uterine fibroma (1.7 ng/ml). Patients with colon (6.8 ng/ml) and renal (5.7 ng/ml) carcinoma had similar values of interleukin-10 but did not significantly differ from controls. Interleukin-10 is known to suppress the functions of both T lymphocytes and macrophages, working as a general dampener of the immune and inflammatory responses. The observation of increased circulating levels of interleukin-10 in cancer patients may have important implications for future investigations, immunological monitoring and therapeutic intervention on neoplastic patients, and suggests a mechanism for tumour cells escaping from immune surveillance.

References (27)

K. Taga et al.
Human interleukin-10 can directly inhibit T-cell growth
Blood
(1993)
W.H. Gotlieb et al.
Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers
Cytokine
(1992)
P. Merville et al.
Serum interleukin 10 in early stage multiple myeloma
Lancet
(1992)
J.Y. Blay et al.
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
Blood
(1993)
T.R. Mosmann et al.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties
Annu. Rev. Immunol.
(1989)
C.A. Janeway et al.
CD4⁺ T cells: specificity and function
Immunol. Rev.
(1988)
F. Powrie et al.
Cytokine regulation of T-cell function: potential for therapeutic intervention
Immunol. Today
(1993)
G. Del Prete et al.
Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production
J. Immunol.
(1993)
K. Taga et al.
IL-10 inhibits human T cell proliferation and IL-2 production
J. Irnmunol.
(1992)
M. Howard et al.
Biological properties of interleukin 10
J.:Clin. Immunol.
(1992)

P. Pisa et al.

Selective expression of interleukin-10, interferon γ, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies

S. Krüger-Krasagakes et al.

Expression of interleukin-10 in human melanoma

Br. J. Cancer

(1994)

L. Filgueira et al.

Cytokine gene transcription in renal cell carcinoma

Br. J. Surg.

(1993)

Cited by (151)

Rational combination immunotherapeutic approaches for effective cancer treatment
2019, Journal of Controlled Release
Citation Excerpt :
The last stage, “escape,” arises when cancer cells develop the ability to evade immune recognition and destruction and grow in an environment of “immune tolerance.” In the escape phase, tumors use three mechanisms to alter immune response: (1) down-regulation of tumor-associated antigens (TAAs) and costimulatory molecules, resulting in reduced immune recognition and stimulation [34–36], (2) increase in resistance against immune cytotoxic effectors (e.g. STAT3) or expression of anti-apoptotic proteins (e.g. BCL-2, Her2/neu) [37,38], and (3) formation of an immunosuppressive tumor microenvironment (TME) by producing immunosuppressive molecules (e.g. VEGF, IL-10, TGF-β) [39–41], inducing the development and expansion of immunosuppressive T regulatory (Treg) cells [42] and activating adaptive immune resistance via immune checkpoint components (e.g., CTLA-4, PD-1/PD-L1) [43]. To generate an effective antitumor response, cancer immunotherapy has to overcome two main obstacles: natural immune tolerance towards self-antigens, which halts T cell activation, and tumor-induced immunosuppression, which significantly limits the therapeutic efficacy of immunotherapy.
Immunotherapy is an important mode of cancer treatment. Over the past decades, immunotherapy has improved the clinical outcome for cancer patients. However, in many cases, mutations in cancer cells, lack of selectivity, insufficiency of tumor-reactive T cells, and host immunosuppression limit the clinical benefit of immunotherapy. Combination approaches in immunotherapy may overcome these obstacles. Accumulating evidence demonstrates that combination immunotherapy is the future of cancer treatment. However, designing safe and rational combinations of immunotherapy with other treatment modalities is critical. This review will discuss the optimal immunotherapy-based combinations mainly with respect to the mechanisms of action of individual therapeutic agents that target multiple steps in evasion and progression of tumor.
Genetic polymorphism of interleukin-10 (-A592C) among oral cancer with squamous cell carcinoma
2017, Archives of Oral Biology
Interleukin-10 (IL-10) is a pleiotropic cytokine with either immunosuppressive or immunostimulative activities. It has been reported that in cancer, the promoter region polymorphism of IL-10 (-A592C) alters both the expression and serum levels of this cytokine. In the present study, we have addressed the question as to whether the single nucleotide polymorphisms (SNPs) at positions −592 A/C in the IL-10 gene promoter, could predispose an individual to oral squamous cell carcinoma (OSCC).
We analyzed the genotype of the IL-10 (-A592C) gene, in 250 histopathologically confirmed OSCC patients and similar number of healthy volunteers taken as controls, in an Indian population by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Allele and genotype frequencies were analyzed by the Student's t-test and the chi-squared test, and strength of associations by the odds ratio (OR) with 95% confidence intervals.
The genotype and allele distribution of IL-10 (-A592C) gene polymorphism was significantly different between OSCC cases and controls (genotype AA vs AC: OR 2.87; 95 % CI 1.50–5.48; p = 0.0016 and AA vs CC: OR 4.08; 95 % CI 1.98–8.41; p = 0.0002). The −592 C alleles were found to be significantly different among OSCC cases and controls (OR: 1.44, 95% CI: 1.12–1.85, p < 0.0051).
The IL-10 gene promoter region (-592) A/C polymorphism is significantly associated with reduced risk of OSCC. The OSCC group had a significantly greater frequency of genotype AA as compared to control group.
Analysis of Mutational Status of IGHV, and Cytokine Polymorphisms as Prognostic Factors in Chronic Lymphocytic Leukemia: The Romanian Experience
2024, International Journal of Molecular Sciences
Immuno-oncology-microbiome axis of gastrointestinal malignancy
2023, World Journal of Gastrointestinal Oncology
Fungal Microbiota Dysbiosis and Ecological Alterations in Gastric Cancer
2022, Frontiers in Microbiology
The Immunogenetics of Melanoma
2022, Advances in Experimental Medicine and Biology

View all citing articles on Scopus

View full text

Increased interleukin-10 serum levels in patients with solid tumours

Abstract

Blood

Cytokine

Lancet

Blood

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

Annu. Rev. Immunol.

CD4+ T cells: specificity and function

Immunol. Rev.

Cytokine regulation of T-cell function: potential for therapeutic intervention

Immunol. Today

Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production

J. Immunol.

IL-10 inhibits human T cell proliferation and IL-2 production

J. Irnmunol.

Biological properties of interleukin 10

J.:Clin. Immunol.

Selective expression of interleukin-10, interferon γ, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies

Expression of interleukin-10 in human melanoma

Br. J. Cancer

Cytokine gene transcription in renal cell carcinoma

Br. J. Surg.

CD4⁺ T cells: specificity and function